Structural mass spectrometry in protein therapeutics discovery.
The protein therapeutics market is one of the highest growing segments of the pharmaceutical industry with an estimated global market value of $77 billion by 2011 (Global Protein Therapeutics Market report by RNCOS: Delhi, India, 2009). This growth has been fueled by several advantages that protein drugs can offer such as higher specificity, reduced side effects, and faster development time compared to small molecule drugs. Major pharmaceutical companies are strategically shifting gears toward protein therapeutics and gradually increasing the biologics portion of their pipelines. Consequently, in the present pharmaceutical industry, there is a rapid growth in the number and types of protein structural mass spectrometry analyses, particularly during the discovery phase where an abundance of new drug candidates are being investigated. This perspective article discusses the role of protein structural mass spectrometry during the discovery of protein therapeutics with focus on recombinant protein production quality control and structural biology applications. The current challenges in technologies associated with this field and the analytical prospects for the future direction will be also discussed.
Kim
Yeoun Jin
YJ
Gene Expression and Protein Biochemistry, Applied Biotechnologies, Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, USA. yeounjin.kim@bms.com
Doyle
Michael L
ML
D004353:Drug Evaluation, Preclinical; D006031:Glycosylation; D013058:Mass Spectrometry / Q000379:methods* / Q000592:standards; D008970:Molecular Weight; D017434:Protein Structure, Tertiary; D011786:Quality Control; D011994:Recombinant Proteins / Q000737:chemistry* / Q000235:genetics / Q000592:standards
D011994:Recombinant Proteins